Although only a small proportion of KRAS mutation patients enrolled in the mCohort were diagnosed with stage I or II disease, KRAS mutation seems to be an early event that might drive lung cancer development [18, 21, 22, 25]. Here, KRAS is linked to lung carcinoma.